Graph AI, a startup growing AI software program for pharmaceutical affected person security operations, has raised $13.3 million in a Sequence A funding spherical led by Perception Companions.

Present investor Bessemer Enterprise Companions additionally took half within the financing, which Graph AI stated will help its growth throughout the US and Europe.

The most recent investment follows a $3 million seed spherical led by Bessemer in October 2025.

Based in 2024, Graph AI develops Graph Security, a platform supposed to automate components of pharmacovigilance, the monitoring and administration of potential security issues related to medicines.

The startup stated pharmaceutical security groups nonetheless spend vital quantities of time on guide processing and operational duties.

Graph Security combines AI with predetermined controls, validation layers and end-to-end audit trails, with the goal of permitting supply information and system outputs to be traced and reviewed by folks.

The startup claims that in dwell deployments its software program had diminished the time taken to course of security instances from greater than three hours to lower than 10 minutes, whereas reducing working prices by as a lot as 66%.

Raghav Parvataraju, CEO of Graph AI, stated pharmacovigilance had historically handled rising case volumes by including workers and processes round older techniques.

“We consider intelligence can change that. Graph Security offers security specialists an clever system that takes on operational complexity, whereas preserving traceability, accountability, and human oversight on the heart. We’re not changing human judgment, we’re constructing expertise that permits specialists to use it the place it issues most,” he stated.

Graph AI has introduced two modules to market since its seed spherical.

Its Consumption module is designed to seize and triage incoming experiences of hostile occasions throughout totally different channels, whereas Nucleus is a security database that automates case processing.

A 3rd module, Report, which is designed to automate combination security reporting, is because of launch in September.

The startup can be engaged on Sign, a deliberate module supposed to establish rising security alerts and patterns throughout instances.

It had onboarded pharmaceutical and biotechnology clients in North America and different markets, and had secured design partnerships for modules nonetheless below improvement.

Richard Matus, principal at Perception Companions, stated pharmaceutical corporations wanted to handle affected person security precisely however usually didn’t wish to combine a spread of separate techniques themselves.

“We consider that is an ideal downside for an AI workforce that lives inside this business with full focus,” he stated.

“Affected person security ought to run an clever, built-in platform, not fragmented instruments and guide handoffs,” he stated.

Graph AI stated Graph Security had been designed as regards to relevant regulatory necessities and altering expectations round using AI in medicines improvement and affected person security.

The startup cited the US Meals and Drug Administration’s framework for assessing the credibility of AI fashions used to help regulatory decision-making. That framework kinds a part of draft FDA steering and incorporates non-binding suggestions.

It additionally cited the European Union’s AI Act and a report revealed by the Council for Worldwide Organizations of Medical Sciences’ Working Group XIV on using AI in pharmacovigilance.